Immunyx Pharma

Company Overview

Snapshot

Founded in February 2021 by Seth Salpeter, Immunyx Pharma operates with 1–10 employees. The company has secured funding across one round from one investor, VLX Ventures, to advance its drug development efforts.

Business overview

Immunyx Pharma is a drug development company focused on modulating neutrophil function to treat various diseases. The company utilizes a platform technology that specifically manipulates neutrophils using targeted nanoparticles to develop new therapies. Immunyx Pharma serves the pharmaceutical and life sciences industries, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Company Intelligence Q&A

When was Immunyx Pharma founded?

Immunyx Pharma was founded in February 2021.

Who is a co-founder of Immunyx Pharma?

Seth Salpeter is a co-founder and CEO of Immunyx Pharma.

What is Immunyx Pharma's primary focus?

Immunyx Pharma focuses on immune modulation through drug development, specifically by modulating neutrophil function to treat diseases.

What technology underpins Immunyx Pharma's approach?

Immunyx Pharma's technology is based on years of basic and translational research by professors Zvika Granot and Zvi Fridlender at the Hebrew University, focusing on neutrophil-targeting nanoparticles.